

Frank Berthold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6038680/publications.pdf>

Version: 2024-02-01

88
papers

6,749
citations

87723

38
h-index

62479

80
g-index

93
all docs

93
docs citations

93
times ranked

6807
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in Risk Classification and Treatment Strategies for Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3008-3017.	0.8	637
2	Telomerase activation by genomic rearrangements in high-risk neuroblastoma. <i>Nature</i> , 2015, 526, 700-704.	13.7	478
3	Neuroblastoma Screening at One Year of Age. <i>New England Journal of Medicine</i> , 2002, 346, 1047-1053.	13.9	381
4	Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. <i>Lancet Oncology</i> , The, 2005, 6, 649-658.	5.1	350
5	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. <i>Genome Biology</i> , 2015, 16, 133.	3.8	325
6	Metabolic activity and clinical features of primary ganglioneuromas. <i>Cancer</i> , 2001, 91, 1905-1913.	2.0	281
7	Localized Infant Neuroblastomas Often Show Spontaneous Regression: Results of the Prospective Trials NB95-S and NB97. <i>Journal of Clinical Oncology</i> , 2008, 26, 1504-1510.	0.8	263
8	Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. <i>Journal of Clinical Oncology</i> , 2011, 29, 3286-3292.	0.8	248
9	Clinical Significance of Tumor-Associated Inflammatory Cells in Metastatic Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3525-3532.	0.8	236
10	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. <i>Journal of Clinical Oncology</i> , 2017, 35, 2580-2587.	0.8	219
11	A mechanistic classification of clinical phenotypes in neuroblastoma. <i>Science</i> , 2018, 362, 1165-1170.	6.0	213
12	Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. <i>International Journal of Cancer</i> , 2001, 93, 445-449.	2.3	161
13	Consolidation Treatment With Chimeric Anti-GD2-Antibody ch14.18 in Children Older Than 1 Year With Metastatic Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 3549-3557.	0.8	140
14	Cystic Craniopharyngioma: Long-term Results after Intracavitary Irradiation with Stereotactically Applied Colloidal ^{125}I -Emitting Radioactive Sources. <i>Neurosurgery</i> , 1997, 40, 263-270.	0.6	131
15	Role of Surgery in the Treatment of Patients With Stage 4 Neuroblastoma Age 18 Months or Older at Diagnosis. <i>Journal of Clinical Oncology</i> , 2013, 31, 752-758.	0.8	115
16	Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy. <i>BMC Cancer</i> , 2011, 11, 21.	1.1	113
17	Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: Results of German trials. <i>Pediatric Blood and Cancer</i> , 2011, 56, 578-583.	0.8	110
18	Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. <i>BMC Cancer</i> , 2016, 16, 542.	1.1	110

#	ARTICLE	IF	CITATIONS
19	Neuroblastoma. <i>Drugs</i> , 2000, 59, 1261-1277.	4.9	105
20	Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project. <i>European Journal of Cancer</i> , 2011, 47, 561-571.	1.3	94
21	The prognostic impact of functional imaging with 123I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: Results of the German Neuroblastoma Trial NB97. <i>European Journal of Cancer</i> , 2008, 44, 1552-1558.	1.3	88
22	Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979â€“2015. <i>Paediatric Drugs</i> , 2017, 19, 577-593.	1.3	86
23	Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial. <i>Leukemia</i> , 2018, 32, 1657-1669.	3.3	86
24	<i>PHOX2B</i> Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 5443-5449.	0.8	83
25	Iodine-123 Metaiodobenzylguanidine Scintigraphy Scoring Allows Prediction of Outcome in Patients With Stage 4 Neuroblastoma: Results of the Cologne Interscore Comparison Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 944-951.	0.8	80
26	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. <i>Clinical Cancer Research</i> , 2015, 21, 1904-1915.	3.2	80
27	Intensified External-Beam Radiation Therapy Improves the Outcome of Stage 4 Neuroblastoma in Children > 1 Year with Residual Local Disease. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 389-394.	1.0	76
28	2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors. <i>Klinische Padiatrie</i> , 2017, 229, 147-167.	0.2	76
29	Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. <i>Cancer</i> , 2017, 123, 1095-1105.	2.0	75
30	THROMBOTECT â€“ a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents. <i>Haematologica</i> , 2019, 104, 756-765.	1.7	74
31	Detecting Minimal Residual Disease in Neuroblastoma: The Superiority of a Panel of Real-Time Quantitative PCR Markers. <i>Clinical Chemistry</i> , 2009, 55, 1316-1326.	1.5	65
32	Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18Âmonths. <i>BMC Cancer</i> , 2017, 17, 520.	1.1	63
33	Smallest region of overlapping deletion in 1p36 in human neuroblastoma: A 1 Mbp cosmid and PAC contig. <i>Genes Chromosomes and Cancer</i> , 2001, 31, 228-239.	1.5	61
34	Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2007, 133, 653-661.	1.2	60
35	Prognostic significance of DNA di-tetraploidy in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2001, 36, 83-92.	1.0	57
36	The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. <i>Cancer Letters</i> , 2005, 228, 257-266.	3.2	48

#	ARTICLE	IF	CITATIONS
37	Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence*. <i>Pediatric Blood and Cancer</i> , 2017, 64, 46-56.	0.8	44
38	FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2003, 41, 30-35.	1.0	42
39	Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma. <i>Molecular Oncology</i> , 2016, 10, 344-359.	2.1	36
40	Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR. <i>Annals of Oncology</i> , 2020, 31, 422-429.	0.6	36
41	Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis?. <i>Medical and Pediatric Oncology</i> , 2000, 35, 683-687.	1.0	35
42	Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma. <i>European Journal of Radiology</i> , 2010, 74, e1-e5.	1.2	35
43	Testicular and paratesticular involvement by metastatic neuroblastoma. <i>Cancer</i> , 2000, 88, 2636-2641.	2.0	33
44	Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1932-1939.	0.8	32
45	Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation. <i>British Journal of Cancer</i> , 2018, 119, 282-290.	2.9	30
46	Telomerase Is a Prognostic Marker of Poor Outcome and a Therapeutic Target in Neuroblastoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-20.	1.5	29
47	A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28794.	0.8	29
48	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. <i>Expert Opinion on Drug Discovery</i> , 2017, 12, 1-11.	2.5	28
49	The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28359.	0.8	28
50	Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. <i>JCI Insight</i> , 2018, 3, .	2.3	28
51	Telomerase is a strong indicator for assessing the proneness to progression in neuroblastomas. <i>Medical and Pediatric Oncology</i> , 2000, 35, 651-655.	1.0	27
52	ecancermedalscience. <i>Ecancermedalscience</i> , 2014, 8, 463.	0.6	26
53	Immunotherapeutic strategies in neuroblastoma: Antitumoral activity of deglycosylated ricin A conjugated anti-CD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. <i>Medical and Pediatric Oncology</i> , 2001, 36, 185-189.	1.0	26
54	Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment. <i>Neoplasia</i> , 2017, 19, 982-990.	2.3	26

#	ARTICLE	IF	CITATIONS
55	Rapid COJEC versus standard induction therapies for high-risk neuroblastoma. The Cochrane Library, 2016, 2016, CD010774.	1.5	25
56	Classification of neuroblastoma patients by published gene-expression markers reveals a low sensitivity for unfavorable courses of MYCN non-amplified disease. Cancer Letters, 2007, 250, 250-267.	3.2	22
57	Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma. Pediatric Blood and Cancer, 2015, 62, 1368-1373.	0.8	22
58	Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Cancer, 2002, 94, 854-861.	2.0	21
59	Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. Pediatric Hematology and Oncology, 2017, 34, 308-319.	0.3	21
60	German neuroblastoma mass screening study at 12 months of age: statistical aspects and preliminary results. Medical and Pediatric Oncology, 1998, 31, 435-441.	1.0	16
61	Stereotactic intracavitary brachytherapy with P-32 for cystic craniopharyngiomas in children. Strahlentherapie Und Onkologie, 2016, 192, 157-165.	1.0	15
62	Feasibility, Risk Profile and Diagnostic Yield of Stereotactic Biopsy in Children and Young Adults with Brain Lesions. Klinische Padiatrie, 2017, 229, 133-141.	0.2	14
63	Biochemical testing for neuroblastoma using plasma free 3-methyldopa, 3-methoxytyramine, and normetanephrine. Pediatric Blood and Cancer, 2020, 67, e28081.	0.8	14
64	Lacking immunocytological GD2 expression in neuroblastoma: Report of 3 cases. Pediatric Blood and Cancer, 2005, 45, 195-201.	0.8	13
65	Correction factors for self-selection when evaluating screening programmes. Journal of Medical Screening, 2016, 23, 44-49.	1.1	12
66	A new risk score for patients after first recurrence of stage 4 neuroblastoma aged 18 months at first diagnosis. Cancer Medicine, 2019, 8, 7236-7243.	1.3	12
67	Î³-secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets. Oncotarget, 2016, 7, 62799-62813.	0.8	12
68	Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients. European Journal of Cancer, 2016, 54, 149-158.	1.3	10
69	Population-based and controlled study to evaluate neuroblastoma screening at one year of age in Germany: Interim results. Medical and Pediatric Oncology, 2000, 35, 701-704.	1.0	9
70	Clinical Presentation. , 2005, , 63-85.		9
71	Lead-time and overdiagnosis estimation in neuroblastoma screening. Statistics in Medicine, 2003, 22, 2877-2892.	0.8	8
72	Computer-Based Exercise Program: Effects of a 12-Week Intervention on Mood and Fatigue in Pediatric Patients With Cancer. Clinical Journal of Oncology Nursing, 2017, 21, E280-E286.	0.3	7

#	ARTICLE	IF	CITATIONS
73	Can we optimise doxorubicin treatment regimens for children with cancer? Pharmacokinetic simulations and a Delphi consensus procedure. <i>BMC Pharmacology & Toxicology</i> , 2020, 21, 37.	1.0	7
74	Are network growth and the contributions to congresses associated with publication success? A pediatric oncology model. <i>PLoS ONE</i> , 2019, 14, e0210994.	1.1	6
75	Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients. <i>Medical and Pediatric Oncology</i> , 2001, 36, 199-202.	1.0	5
76	Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab041.	1.4	5
77	Asymmetric salivary gland ¹²³ I-meta-iodobenzylguanidine uptake in a patient with cervical neuroblastoma and horner syndrome. <i>Medical and Pediatric Oncology</i> , 2001, 36, 489-490.	1.0	4
78	Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29038.	0.8	4
79	Plasma Neurotensin: Lack of a Differentiation and Tumor Marker in Children with Neuroblastoma. <i>Pediatric Hematology and Oncology</i> , 1992, 9, 269-272.	0.3	3
80	Retrospective analysis of relapsed abdominal high-risk neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2018, 53, 558-566.	0.8	3
81	The reliability of bone marrow cytology as response criterion in metastatic neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28819.	0.8	2
82	Confirmatory adaptive group sequential designs for single-arm phase II studies with multiple time-to-event endpoints. <i>Biometrical Journal</i> , 2022, 64, 312-342.	0.6	2
83	Metastatic neuroblastoma in infancy: What does the pattern of metastases contribute to prognosis?. , 2000, 35, 683.		2
84	Genetic Alterations and Resectability Predict Outcome in Patients with Neuroblastoma Assigned to High-Risk Solely by MYCN Amplification. <i>Cancers</i> , 2021, 13, 4360.	1.7	1
85	Hypercalcemia is a frequent side effect of ¹³ cis-retinoic acid treatment in patients with high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2021, , e29374.	0.8	1
86	From a single meeting to a scientific community: Quantification of the "Advances in Neuroblastoma Research Association" network. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27696.	0.8	0
87	Solide Tumoren. , 2007, , 805-870.		0
88	Response to Front-Line Imatinib Treatment in Children and Adolescents with CML - Data from a Large Pediatric Cohort. <i>Blood</i> , 2017, 130, 898-898.	0.6	0